Novo Nordisk A S NVO
What this company does
Written from the business description in NOVO NORDISK A S's annual report to the U.S. Securities and Exchange Commission, filed 4 February 2026. Every sentence was checked against that document before publication.
Revenue compounded at +19.5% a year over five years — but profit grew slower: net income at +19.4%.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Not available in our data for this period.
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue DKK B | 309.1 | 290.4 | 232.3 | 177.0 | 140.8 | 126.9 | 122.0 |
| Operating income DKK B | 127.7 | 128.3 | 102.6 | 74.8 | 58.6 | 54.1 | 52.5 |
| EBITDA DKK B | 142.3 | 136.9 | 109.9 | 81.4 | 64.7 | 59.9 | 58.1 |
| Income tax DKK B | 28.1 | 26.2 | 21.0 | 13.5 | 11.3 | 11.0 | 9.6 |
| Net income DKK B | 102.4 | 101.0 | 83.7 | 55.5 | 47.8 | 42.1 | 39.0 |
| Free cash flow DKK B | 59.0 | 73.8 | 83.1 | 66.7 | 48.7 | 46.1 | 37.9 |
| EPS, diluted DKK | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 | 18.01 | 16.38 |
| Dividend / sh DKK | 11.70 | 11.40 | 9.40 | 6.20 | 10.40 | 9.10 | · |
| Payout % | 51 | 44 | 38 | 46 | 45 | 48 | 50 |
| ROE % | · | · | · | · | · | · | · |
| Shares out B | 4.44 | 4.44 | 4.46 | 4.50 | 4.62 | 2.35 | 2.40 |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Reconciled in 7 of 19 fiscal years. 62 checks could not be computed.